中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2011年
39期
2765-2768
,共4页
诸葛勇华%陶厚权%王元宇
諸葛勇華%陶厚權%王元宇
제갈용화%도후권%왕원우
胃肿瘤%预后%鞘氨醇激酶
胃腫瘤%預後%鞘氨醇激酶
위종류%예후%초안순격매
Stomach neoplasms%Prognosis%Sphingosine kinase
目的 探讨鞘氨醇激酶1 (SPHK1)在胃癌组织中的表达及其与胃癌浸润、转移及预后的关系.方法 应用免疫组织化学SP法,检测浙江省人民医院2001年1月至2005年12月206例石蜡固定的胃癌组织和同期的40例非肿瘤胃黏膜中SPHK1的表达.结果 在40例非肿瘤胃黏膜组织中,3例(7.5％) SPHK1蛋白为阳性表达,均为低表达.在206例胃癌组织中,181例(87.9％)SPHK1蛋白阳性表达,明显高于非肿瘤胃黏膜组织(P =0.001),其中高表达126例(61.2％).SPHK1蛋白的表达与浸润深度、淋巴结转移、远处转移及TNM分期有关(P=0.039、0.003、0.020、0.003),而与患者性别、肿瘤部位、肿瘤大小、分化程度和组织学类型无关(均P＞0.05).Ⅰ～Ⅱ和Ⅲ期中SPHK1高表达胃癌患者5年生存率显著低于SPHK1低表达者[53.6％( 15/28)比68.6％( 24/35),7.8％ (6/77)比30.8％(12/39),P=0.009、0.006],Ⅳ期胃癌患者的5年生存率与SPHK1表达无关(P＞0.05),多变量分析表明SPHK1表达、淋巴结转移、远处转移和TNM分期是胃癌患者独立的预后因素.结论 SPHK1的表达与胃癌淋巴结转移和远处转移及预后相关,SPHK1有望成为一个预测肿瘤预后的分子标志物.
目的 探討鞘氨醇激酶1 (SPHK1)在胃癌組織中的錶達及其與胃癌浸潤、轉移及預後的關繫.方法 應用免疫組織化學SP法,檢測浙江省人民醫院2001年1月至2005年12月206例石蠟固定的胃癌組織和同期的40例非腫瘤胃黏膜中SPHK1的錶達.結果 在40例非腫瘤胃黏膜組織中,3例(7.5％) SPHK1蛋白為暘性錶達,均為低錶達.在206例胃癌組織中,181例(87.9％)SPHK1蛋白暘性錶達,明顯高于非腫瘤胃黏膜組織(P =0.001),其中高錶達126例(61.2％).SPHK1蛋白的錶達與浸潤深度、淋巴結轉移、遠處轉移及TNM分期有關(P=0.039、0.003、0.020、0.003),而與患者性彆、腫瘤部位、腫瘤大小、分化程度和組織學類型無關(均P＞0.05).Ⅰ～Ⅱ和Ⅲ期中SPHK1高錶達胃癌患者5年生存率顯著低于SPHK1低錶達者[53.6％( 15/28)比68.6％( 24/35),7.8％ (6/77)比30.8％(12/39),P=0.009、0.006],Ⅳ期胃癌患者的5年生存率與SPHK1錶達無關(P＞0.05),多變量分析錶明SPHK1錶達、淋巴結轉移、遠處轉移和TNM分期是胃癌患者獨立的預後因素.結論 SPHK1的錶達與胃癌淋巴結轉移和遠處轉移及預後相關,SPHK1有望成為一箇預測腫瘤預後的分子標誌物.
목적 탐토초안순격매1 (SPHK1)재위암조직중적표체급기여위암침윤、전이급예후적관계.방법 응용면역조직화학SP법,검측절강성인민의원2001년1월지2005년12월206례석사고정적위암조직화동기적40례비종류위점막중SPHK1적표체.결과 재40례비종류위점막조직중,3례(7.5％) SPHK1단백위양성표체,균위저표체.재206례위암조직중,181례(87.9％)SPHK1단백양성표체,명현고우비종류위점막조직(P =0.001),기중고표체126례(61.2％).SPHK1단백적표체여침윤심도、림파결전이、원처전이급TNM분기유관(P=0.039、0.003、0.020、0.003),이여환자성별、종류부위、종류대소、분화정도화조직학류형무관(균P＞0.05).Ⅰ～Ⅱ화Ⅲ기중SPHK1고표체위암환자5년생존솔현저저우SPHK1저표체자[53.6％( 15/28)비68.6％( 24/35),7.8％ (6/77)비30.8％(12/39),P=0.009、0.006],Ⅳ기위암환자적5년생존솔여SPHK1표체무관(P＞0.05),다변량분석표명SPHK1표체、림파결전이、원처전이화TNM분기시위암환자독립적예후인소.결론 SPHK1적표체여위암림파결전이화원처전이급예후상관,SPHK1유망성위일개예측종류예후적분자표지물.
Objective To explore the clinical significance of sphingosine kinase 1 ( SPHK1 ) in the invasion,metastasis and prognosis of gastric cancer.Methods Immunohistochemistry was employed to analyze the expression of SPHK1 in 206 clinicopathologically characterized gastric cancer cases from January 2001 to December 2005 at Zhejiang Provincial People's Hospital.Results SPHK1 protein was detected in 3 (7.5％ ) of 40 human non-tumor mucosa.All samples expressed the protein at a low level.SPHK1 protein was detected in 181 (87.9％) of 206 human gastric cancer cases.An elevated expression of SPHK1 protein was detected in 126 (61.2％) tumors.And SPHK1 protein was up-regulated in gastric cancer lesions compared with adjacent noncancerous tissues( P =0.001 ).The expression of SPHK1 was correlated with the depth of invasion,lymph node metastasis,distant metastasis and TNM stage ( P =0.039,0.003,0.020,0.003).In stages Ⅰ - Ⅱ and Ⅲ,the 5-year survival rate of the patients with a high expression of SPHK1 was significantly lower than those with a low expression (53.6％ ( 15/28 )vs 68.6％ (24/35),7.8％ (6/ 77) vs 30.8％ ( 12/39 ),P =0.009,0.006).In stage ⅣV,the expression of SPHK1 was not correlated with the 5-year survival rate ( P ＞ 0.05 ).Further multivariate analysis suggested that lymph node metastasis,distant metastasis,TNM stage and the up-regulation of SPHK1 were independent prognostic indicators for gastric cancer.Conclusion The expression of SPHK1 in gastric cancer is significantly associated with lymph node metastasis,distant metastasis and a poor prognosis.SPHK1 may become a useful marker of predicting tumor progression and prognosis.
